HCW Biologics Inc Total Liabilities
HCW Biologics Inc total liabilities. Based on the latest financial reports, HCW Biologics Inc (HCWB) has total liabilities worth $19.34 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HCWB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HCW Biologics Inc (2019–2025)
Total liabilities of HCW Biologics Inc from 2019 to 2025. This chart illustrates how HCW Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of HCW Biologics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
HCW Biologics Inc Competitors by Total Liabilities
The table below lists competitors of HCW Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
USA | $4.70 Million |
|
Literacy Capital PLC
LSE:BOOK
|
UK | GBX12.94 Million |
|
Human Xtensions Ltd
TA:HUMX
|
Israel | ILA1.10 Million |
|
Himalaya Energi Perkasa Tbk PT
JK:HADE
|
Indonesia | Rp1.28 Billion |
|
Celtic PLC
LSE:CCP
|
UK | GBX89.90 Million |
|
Downing Renewables & Infrastructure Trust PLC
LSE:DORE
|
UK | GBX1.79 Million |
|
Martello Technologies Group Inc
V:MTLO
|
Canada | CA$23.14 Million |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
India | Rs524.68 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down HCW Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HCWB asset base.
Liquidity & Leverage Metrics
HCW Biologics Inc Total Liabilities Ratios Explained
HCW Biologics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HCW Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HCW Biologics Inc (2019–2025)
The table below shows the annual total liabilities of HCW Biologics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.76 Million | -41.21% |
| 2024-12-31 | $37.01 Million | +145.86% |
| 2023-12-31 | $15.05 Million | +60.46% |
| 2022-12-31 | $9.38 Million | +304.06% |
| 2021-12-31 | $2.32 Million | +131.91% |
| 2020-12-31 | $1.00 Million | -6.10% |
| 2019-12-31 | $1.07 Million | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more